| Outcome | Assumption | Study | Risk ratio | Lower 95% CI | Upper 95% CI | % change from available case analysis |
| Loss of 3+ lines visual acuity at 6 months | Missing at random (available case analysis) | AMDRT 2004 | 0.778 | 0.326 | 1.856 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | AMDRT 2004 | 0.742 | 0.324 | 1.701 | 5% | |
| Odds of outcome in not observed half odds of outcome in observed | AMDRT 2004 | 0.816 | 0.336 | 1.981 | ‐5% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | AMDRT 2004 | 0.958 | 0.403 | 2.274 | ‐23% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | AMDRT 2004 | 0.632 | 0.269 | 1.482 | 19% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | AMDRT 2004 | 1 | 0.459 | 2.178 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | AMDRT 2004 | 0.955 | 0.467 | 1.955 | 5% | |
| Odds of outcome in not observed half odds of outcome in observed | AMDRT 2004 | 1.047 | 0.466 | 2.351 | ‐5% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | AMDRT 2004 | 1.321 | 0.611 | 2.856 | ‐32% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | AMDRT 2004 | 0.757 | 0.355 | 1.613 | 24% | |
| Loss of 6+ lines visual acuity at 6 months | Missing at random (available case analysis) | AMDRT 2004 | 0.25 | 0.057 | 1.095 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | AMDRT 2004 | 0.244 | 0.057 | 1.037 | 2% | |
| Odds of outcome in not observed half odds of outcome in observed | AMDRT 2004 | 0.261 | 0.059 | 1.157 | ‐4% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | AMDRT 2004 | 0.318 | 0.073 | 1.383 | ‐27% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | AMDRT 2004 | 0.2 | 0.046 | 0.867 | 20% | |
| Loss of 6+ lines visual acuity at 12 months | Missing at random (available case analysis) | AMDRT 2004 | 0.667 | 0.208 | 2.133 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | AMDRT 2004 | 0.644 | 0.213 | 1.946 | 3% | |
| Odds of outcome in not observed half odds of outcome in observed | AMDRT 2004 | 0.697 | 0.213 | 2.28 | ‐4% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | AMDRT 2004 | 0.934 | 0.296 | 2.949 | ‐40% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | AMDRT 2004 | 0.48 | 0.153 | 1.506 | 28% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | Bergink 1998 | 0.586 | 0.326 | 1.054 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Bergink 1998 | 0.575 | 0.328 | 1.007 | 2% | |
| Odds of outcome in not observed half odds of outcome in observed | Bergink 1998 | 0.608 | 0.332 | 1.112 | ‐4% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Bergink 1998 | 0.655 | 0.363 | 1.18 | ‐12% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Bergink 1998 | 0.534 | 0.3 | 0.95 | 9% | |
| Loss of 6+ lines visual acuity at 12 months | Missing at random (available case analysis) | Bergink 1998 | 0.213 | 0.067 | 0.683 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Bergink 1998 | 0.209 | 0.067 | 0.655 | 2% | |
| Odds of outcome in not observed half odds of outcome in observed | Bergink 1998 | 0.223 | 0.069 | 0.721 | ‐5% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Bergink 1998 | 0.247 | 0.077 | 0.791 | ‐16% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Bergink 1998 | 0.188 | 0.059 | 0.597 | 12% | |
| Loss of 3+ lines visual acuity at 6 months | Missing at random (available case analysis) | Jaakkola 2005 | 0.517 | 0.261 | 1.024 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Jaakkola 2005 | 0.506 | 0.258 | 0.994 | 2% | |
| Odds of outcome in not observed half odds of outcome in observed | Jaakkola 2005 | 0.529 | 0.266 | 1.053 | ‐2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Jaakkola 2005 | 0.542 | 0.273 | 1.076 | ‐5% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Jaakkola 2005 | 0.493 | 0.25 | 0.973 | 5% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | Jaakkola 2005 | 0.91 | 0.599 | 1.382 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Jaakkola 2005 | 0.886 | 0.588 | 1.337 | 3% | |
| Odds of outcome in not observed half odds of outcome in observed | Jaakkola 2005 | 0.937 | 0.613 | 1.43 | ‐3% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Jaakkola 2005 | 0.937 | 0.613 | 1.43 | ‐3% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Jaakkola 2005 | 0.886 | 0.588 | 1.337 | 3% | |
| Loss of 3+ lines visual acuity at 24 months | Missing at random (available case analysis) | Jaakkola 2005 | 1.034 | 0.789 | 1.356 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Jaakkola 2005 | 1.026 | 0.79 | 1.334 | 1% | |
| Odds of outcome in not observed half odds of outcome in observed | Jaakkola 2005 | 1.045 | 0.79 | 1.383 | ‐1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Jaakkola 2005 | 1.063 | 0.808 | 1.399 | ‐3% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Jaakkola 2005 | 1.009 | 0.772 | 1.319 | 2% | |
| Loss of 6+ lines visual acuity at 6 months | Missing at random (available case analysis) | Jaakkola 2005 | 0.139 | 0.018 | 1.084 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Jaakkola 2005 | 0.134 | 0.017 | 1.037 | 4% | |
| Odds of outcome in not observed half odds of outcome in observed | Jaakkola 2005 | 0.144 | 0.018 | 1.119 | ‐4% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Jaakkola 2005 | 0.149 | 0.019 | 1.154 | ‐7% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Jaakkola 2005 | 0.13 | 0.017 | 1.005 | 6% | |
| Loss of 6+ lines visual acuity at 12 months | Missing at random (available case analysis) | Jaakkola 2005 | 0.545 | 0.256 | 1.16 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Jaakkola 2005 | 0.522 | 0.247 | 1.105 | 4% | |
| Odds of outcome in not observed half odds of outcome in observed | Jaakkola 2005 | 0.565 | 0.264 | 1.207 | ‐4% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Jaakkola 2005 | 0.565 | 0.264 | 1.207 | ‐4% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Jaakkola 2005 | 0.522 | 0.247 | 1.105 | 4% | |
| Loss of 6+ lines visual acuity at 24 months | Missing at random (available case analysis) | Jaakkola 2005 | 0.947 | 0.588 | 1.528 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Jaakkola 2005 | 0.934 | 0.586 | 1.489 | 1% | |
| Odds of outcome in not observed half odds of outcome in observed | Jaakkola 2005 | 0.961 | 0.592 | 1.562 | ‐1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Jaakkola 2005 | 0.995 | 0.617 | 1.606 | ‐5% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Jaakkola 2005 | 0.902 | 0.562 | 1.448 | 5% | |
| Loss of 3+ lines visual acuity at 24 months | Missing at random (available case analysis) | Kobayashi 2000 | 0.584 | 0.429 | 0.795 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Kobayashi 2000 | 0.598 | 0.447 | 0.802 | ‐2% | |
| Odds of outcome in not observed half odds of outcome in observed | Kobayashi 2000 | 0.574 | 0.415 | 0.794 | 2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Kobayashi 2000 | 0.62 | 0.458 | 0.84 | ‐6% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Kobayashi 2000 | 0.554 | 0.405 | 0.758 | 5% | |
| Loss of 6+ lines visual acuity at 24 months | Missing at random (available case analysis) | Kobayashi 2000 | 0.523 | 0.272 | 1.006 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Kobayashi 2000 | 0.52 | 0.277 | 0.975 | 1% | |
| Odds of outcome in not observed half odds of outcome in observed | Kobayashi 2000 | 0.535 | 0.274 | 1.044 | ‐2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Kobayashi 2000 | 0.606 | 0.316 | 1.163 | ‐16% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Kobayashi 2000 | 0.459 | 0.24 | 0.876 | 12% | |
| Loss of 3+ lines visual acuity at 6 months | Missing at random (available case analysis) | Marcus 2001 | 1.055 | 0.709 | 1.57 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Marcus 2001 | 1.014 | 0.696 | 1.478 | 4% | |
| Odds of outcome in not observed half odds of outcome in observed | Marcus 2001 | 1.105 | 0.73 | 1.672 | ‐5% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Marcus 2001 | 1.135 | 0.755 | 1.706 | ‐8% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Marcus 2001 | 0.987 | 0.673 | 1.448 | 6% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | Marcus 2001 | 1.216 | 0.913 | 1.621 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Marcus 2001 | 1.178 | 0.904 | 1.535 | 3% | |
| Odds of outcome in not observed half odds of outcome in observed | Marcus 2001 | 1.265 | 0.927 | 1.727 | ‐4% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Marcus 2001 | 1.298 | 0.959 | 1.757 | ‐7% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Marcus 2001 | 1.148 | 0.873 | 1.51 | 6% | |
| Loss of 6+ lines visual acuity at 6 months | Missing at random (available case analysis) | Marcus 2001 | 0.581 | 0.179 | 1.889 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Marcus 2001 | 0.533 | 0.168 | 1.696 | 8% | |
| Odds of outcome in not observed half odds of outcome in observed | Marcus 2001 | 0.621 | 0.19 | 2.035 | ‐7% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Marcus 2001 | 0.661 | 0.203 | 2.152 | ‐14% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Marcus 2001 | 0.501 | 0.157 | 1.604 | 14% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | Marcus 2001 | 1.226 | 0.562 | 2.677 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Marcus 2001 | 1.142 | 0.541 | 2.41 | 7% | |
| Odds of outcome in not observed half odds of outcome in observed | Marcus 2001 | 1.297 | 0.585 | 2.873 | ‐6% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Marcus 2001 | 1.423 | 0.65 | 3.112 | ‐16% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Marcus 2001 | 1.041 | 0.487 | 2.227 | 15% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | RAD 1999 | 0.972 | 0.735 | 1.285 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | RAD 1999 | 0.986 | 0.754 | 1.288 | ‐1% | |
| Odds of outcome in not observed half odds of outcome in observed | RAD 1999 | 0.957 | 0.717 | 1.277 | 2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | RAD 1999 | 1.041 | 0.79 | 1.371 | ‐7% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | RAD 1999 | 0.906 | 0.684 | 1.2 | 7% | |
| Loss of 3+ lines visual acuity at 6 months | Missing at random (available case analysis) | SFRADS 2002 | 0.827 | 0.598 | 1.143 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | SFRADS 2002 | 0.812 | 0.594 | 1.111 | 2% | |
| Odds of outcome in not observed half odds of outcome in observed | SFRADS 2002 | 0.845 | 0.607 | 1.177 | ‐2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | SFRADS 2002 | 0.886 | 0.64 | 1.227 | ‐7% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | SFRADS 2002 | 0.774 | 0.562 | 1.065 | 6% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | SFRADS 2002 | 0.986 | 0.768 | 1.266 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | SFRADS 2002 | 0.977 | 0.767 | 1.243 | 1% | |
| Odds of outcome in not observed half odds of outcome in observed | SFRADS 2002 | 0.998 | 0.772 | 1.29 | ‐1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | SFRADS 2002 | 1.033 | 0.804 | 1.328 | ‐5% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | SFRADS 2002 | 0.943 | 0.737 | 1.208 | 4% | |
| Loss of 3+ lines visual acuity at 24 months | Missing at random (available case analysis) | SFRADS 2002 | 0.869 | 0.732 | 1.031 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | SFRADS 2002 | 0.876 | 0.745 | 1.03 | ‐1% | |
| Odds of outcome in not observed half odds of outcome in observed | SFRADS 2002 | 0.862 | 0.718 | 1.033 | 1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | SFRADS 2002 | 0.905 | 0.764 | 1.073 | ‐4% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | SFRADS 2002 | 0.834 | 0.701 | 0.993 | 4% | |
| Loss of 6+ lines visual acuity at 6 months | Missing at random (available case analysis) | SFRADS 2002 | 0.842 | 0.478 | 1.482 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | SFRADS 2002 | 0.81 | 0.466 | 1.41 | 4% | |
| Odds of outcome in not observed half odds of outcome in observed | SFRADS 2002 | 0.868 | 0.491 | 1.536 | ‐3% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | SFRADS 2002 | 0.929 | 0.528 | 1.635 | ‐10% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | SFRADS 2002 | 0.757 | 0.433 | 1.325 | 10% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | SFRADS 2002 | 0.68 | 0.452 | 1.024 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | SFRADS 2002 | 0.675 | 0.453 | 1.007 | 1% | |
| Odds of outcome in not observed half odds of outcome in observed | SFRADS 2002 | 0.688 | 0.455 | 1.042 | ‐1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | SFRADS 2002 | 0.73 | 0.486 | 1.098 | ‐7% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | SFRADS 2002 | 0.636 | 0.424 | 0.955 | 6% | |
| Loss of 6+ lines visual acuity at 24 months | Missing at random (available case analysis) | SFRADS 2002 | 0.851 | 0.617 | 1.173 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | SFRADS 2002 | 0.858 | 0.631 | 1.166 | ‐1% | |
| Odds of outcome in not observed half odds of outcome in observed | SFRADS 2002 | 0.847 | 0.608 | 1.179 | 0% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | SFRADS 2002 | 0.929 | 0.676 | 1.277 | ‐9% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | SFRADS 2002 | 0.782 | 0.567 | 1.077 | 8% | |
| Loss of 3+ lines visual acuity at 6 months | Missing at random (available case analysis) | Valmaggia 2002 | 0.403 | 0.184 | 0.884 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Valmaggia 2002 | 0.406 | 0.187 | 0.881 | ‐1% | |
| Odds of outcome in not observed half odds of outcome in observed | Valmaggia 2002 | 0.405 | 0.184 | 0.892 | 0% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Valmaggia 2002 | 0.434 | 0.199 | 0.948 | ‐8% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Valmaggia 2002 | 0.379 | 0.173 | 0.828 | 6% | |
| Loss of 3+ lines visual acuity at 12 months | Missing at random (available case analysis) | Valmaggia 2002 | 0.585 | 0.273 | 1.251 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Valmaggia 2002 | 0.606 | 0.292 | 1.258 | ‐4% | |
| Odds of outcome in not observed half odds of outcome in observed | Valmaggia 2002 | 0.575 | 0.266 | 1.246 | 2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Valmaggia 2002 | 0.698 | 0.33 | 1.474 | ‐19% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Valmaggia 2002 | 0.5 | 0.234 | 1.064 | 15% | |
| Loss of 3+ lines visual acuity at 24 months | Missing at random (available case analysis) | Valmaggia 2002 | 0.733 | 0.382 | 1.409 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Valmaggia 2002 | 0.746 | 0.401 | 1.389 | ‐2% | |
| Odds of outcome in not observed half odds of outcome in observed | Valmaggia 2002 | 0.729 | 0.374 | 1.423 | 1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Valmaggia 2002 | 0.868 | 0.456 | 1.651 | ‐18% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Valmaggia 2002 | 0.627 | 0.328 | 1.198 | 14% | |
| Loss of 6+ lines visual acuity at 6 months | Missing at random (available case analysis) | Valmaggia 2002 | 0.065 | 0.004 | 1.113 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Valmaggia 2002 | 0.065 | 0.004 | 1.108 | 0% | |
| Odds of outcome in not observed half odds of outcome in observed | Valmaggia 2002 | 0.066 | 0.004 | 1.122 | ‐2% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Valmaggia 2002 | 0.071 | 0.004 | 1.215 | ‐9% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Valmaggia 2002 | 0.06 | 0.004 | 1.023 | 8% | |
| Loss of 6+ lines visual acuity at 12 months | Missing at random (available case analysis) | Valmaggia 2002 | 0.341 | 0.073 | 1.598 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Valmaggia 2002 | 0.354 | 0.077 | 1.62 | ‐4% | |
| Odds of outcome in not observed half odds of outcome in observed | Valmaggia 2002 | 0.336 | 0.071 | 1.586 | 1% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Valmaggia 2002 | 0.425 | 0.092 | 1.972 | ‐25% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Valmaggia 2002 | 0.28 | 0.06 | 1.303 | 18% | |
| Loss of 6+ lines visual acuity at 24 months | Missing at random (available case analysis) | Valmaggia 2002 | 0.714 | 0.246 | 2.076 | 0% |
| Odds of outcome in not observed twice odds of outcome in observed | Valmaggia 2002 | 0.722 | 0.256 | 2.038 | ‐1% | |
| Odds of outcome in not observed half odds of outcome in observed | Valmaggia 2002 | 0.712 | 0.243 | 2.092 | 0% | |
| Odds of outcome in not observed twice odds of outcome in observed in treatment group and odds of outcome in not observed half odds of outcome in observed in control group | Valmaggia 2002 | 0.882 | 0.307 | 2.536 | ‐24% | |
| Odds of outcome in not observed half odds of outcome in observed in treatment group and odds of outcome in not observed twice odds of outcome in observed in control group | Valmaggia 2002 | 0.584 | 0.202 | 1.682 | 18% |